Literature DB >> 11418624

Cutting edge: Ly49A inhibits TCR/CD3-induced apoptosis and IL-2 secretion.

J Roger1, A Chalifour, S Lemieux, P Duplay.   

Abstract

To evaluate the importance of Ly49A on TCR-induced cellular events, we established clones of the 1F2 T cell hybridoma expressing either Ly49A or a chimeric version, Ly49A/H, where the Ly49A cytoplasmic domain has been replaced by the Ly49H cytoplasmic domain. Ligation of Ly49A, but not Ly49A/H, with its ligand H-2D(d) or anti-Ly49A mAbs caused a specific inhibition of TCR/CD3-induced IL-2 secretion. Moreover, flow cytometry analysis of hypodiploid DNA and annexin V binding revealed that ligation of Ly49A protected cells from apoptosis induced by anti-CD3 mAbs or Ag. In contrast, ligation of the Ly49A/H chimeric receptor had no antiapoptotic effect. In addition, engagement of Ly49A selectively inhibited TCR-induced Fas ligand expression whereas TCR-induced Fas expression was not significantly affected. Expression of Ly49 inhibitory receptors on T cells may represent an important mechanism for the regulation of T cell survival in vivo by inhibiting TCR-induced apoptosis and IL-2 secretion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418624     DOI: 10.4049/jimmunol.167.1.6

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Receptor/ligand avidity determines the capacity of Ly49 inhibitory receptors to interfere with T-cell receptor-mediated activation.

Authors:  Anick Chalifour; Joanne Roger; Suzanne Lemieux; Pascale Duplay
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

Review 2.  Regulation of self-tolerance by Qa-1-restricted CD8(+) regulatory T cells.

Authors:  Hye-Jung Kim; Harvey Cantor
Journal:  Semin Immunol       Date:  2011-12       Impact factor: 11.130

3.  CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice.

Authors:  Hye-Jung Kim; Xuan Wang; Soroosh Radfar; Thomas J Sproule; Derry C Roopenian; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-13       Impact factor: 11.205

4.  Lentiviral interferon: A novel method for gene therapy in bladder cancer.

Authors:  Sharada Mokkapati; Vikram M Narayan; Ganiraju C Manyam; Amy H Lim; Jonathan J Duplisea; Andrea Kokorovic; Tanner S Miest; Anirban P Mitra; Devin Plote; Selvalakshmi Selvaraj Anand; Michael J Metcalfe; Kenneth Dunner; Burles A Johnson; Bogdan A Czerniak; Tiina Nieminen; Tommi Heikura; Seppo Yla-Herttuala; Nigel R Parker; Kimberley S Schluns; David J McConkey; Colin P Dinney
Journal:  Mol Ther Oncolytics       Date:  2022-06-10       Impact factor: 6.311

5.  Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1.

Authors:  Lies Boelen; Bisrat Debebe; Marcos Silveira; Arafa Salam; Julia Makinde; Chrissy H Roberts; Eddie C Y Wang; John Frater; Jill Gilmour; Katie Twigger; Kristin Ladell; Kelly L Miners; Jyothi Jayaraman; James A Traherne; David A Price; Ying Qi; Maureen P Martin; Derek C Macallan; Chloe L Thio; Jacquie Astemborski; Gregory Kirk; Sharyne M Donfield; Susan Buchbinder; Salim I Khakoo; James J Goedert; John Trowsdale; Mary Carrington; Simon Kollnberger; Becca Asquith
Journal:  Sci Immunol       Date:  2018-11-09

6.  Functional Characterization of Ly49+CD8 T-Cells in Both Normal Condition and During Anti-Viral Response.

Authors:  Dmytro Shytikov; Deepak Rohila; Dan Li; Pengfei Wang; Mei Jiang; Mingxu Zhang; Qin Xu; Linrong Lu
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

Review 7.  Hiding in Plain Sight: Virtually Unrecognizable Memory Phenotype CD8+ T cells.

Authors:  Daniel Thiele; Nicole L La Gruta; Angela Nguyen; Tabinda Hussain
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.